Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02424019 · ClinicalTrials.gov registry record · Phase 4
Phase 4 IOP Signals Associated With ILUVIEN®
A Phase 4 study, sponsored by Alimera Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 153
- Enrollment target
NCT02424019: Completed Phase 4 study, sponsored by Alimera Sciences.
NCT02424019 is a Phase 4 study that has completed, run by Alimera Sciences. The registered enrollment target is 153 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02424019, a Phase 4 study, has completed, sponsored by Alimera Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 153 participants
- Enrollment target
Study Summary
This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.
Primary Outcome
Intraocular pressure of the ILUVIEN treated eye
Interventions
- DRUG ILUVIEN 0.19 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2015-05-06 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 4 |
What the finished NCT02424019 record still lists
NCT02424019 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which ILUVIEN 0.19 MG is the first listed.
NCT02424019 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02424019 about?
NCT02424019 is a clinical study titled "Phase 4 IOP Signals Associated With ILUVIEN®". This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.
What is the current status of trial NCT02424019?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 153 participants. The study started on 2015-05-06. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT02424019?
The interventions under investigation include: ILUVIEN 0.19 MG (DRUG).
Who is sponsoring clinical trial NCT02424019?
This trial is sponsored by Alimera Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02424019's enrollment target sits among peer trials
153 530th of 2000 higher than 1,471 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI